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Abstract

DIRECTING MESENCHYMAL STEM CELLS FOR PERIODONTAL REGENERATION
By
Charles Stoianovici
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Dentistry at Virginia Commonwealth University.

Virginia Commonwealth University, 2018

Major Director: Zhao Lin
Assistant Professor, Department of Periodontics,
Virginia Commonwealth University School of Dentistry

Background: Directing autogenous Mesenchymal Stem Cell (MSC) to defect sites has a great
promise in bone regeneration. We designed a MSC specific, bone affinity peptide (E7HA7) by
conjugating E7 with a polyglutamate hydroxyapatite (HA) binding motif. We sought to
characterize the in-vivo releasing pattern and bioactivity of E7HA7. Methods: HA discs were
coated with fluorescent labeled peptides E7HA7, E7HA2 or E7 were subcutaneously implanted
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in Sprague Dawley rats. In an ectopic bone formation model was used to test the in-vivo
bioactivity of E7HA7 conjugated to DBM. Results: E7HA7 showed slower peptide release from
scaffolds in comparison to other groups, being statistically significant at week 2 compared to E7,
and to E7HA2 at week 4 and 8. In ectopic model, the medians for new bone formation in each
group were: iDBM=0.041mm3, iDBM-E7=0.071mm3, aDBM=0.138mm3, and aDBME7=0.192mm3. Conclusions: Conjugation of E7 to polyglutamate bone binding domain showed
slow releasing kinetics and osteoinductive potential.

Keywords: Mesenchymal Stem Cell, Regeneration, Hydroxyapatite, Demineralized Bone Matrix,
Peptide

Introduction
Periodontal Disease
Periodontal disease is one of the most common inflammatory diseases affecting over 50%
of adults in the United States1. It is characterized as inflammation of the supporting tissues of
teeth, which can progressively lead to periodontal pocket formation, suppuration, fibrosis,
destruction of alveolar bone and periodontal ligament (PDL), mobility and eventual tooth
exfoliation. In a study by Becker et al, when periodontal disease remained untreated, patients
continued to have progressive radiographic bone loss and increased in probing depth. When
periodontally hopeless teeth were not treated, patients were at risk of losing 0.36/teeth per year2.
However periodontal disease can be managed with numerous therapies including non-surgical
therapy, surgical therapy, and regenerative methods.
The primary etiological factor in periodontitis is bacterial biofilm and their products,
which cause inflammatory reaction by the host. Eventually, with the continued host mediated
destruction, patients begin to have an apical migration of the junctional epithelium leading to
pocket formation and possible bone loss. With bone loss and apical migration of the junctional
epithelium, pocket formation will continue to propagate forming a favorable anaerobic
environment for bacterial biofilm. In addition to the favorable environment for anaerobic
bacterial species, the bone loss often creates osseous defects in between teeth that makes
treatment even more challenging for the clinician.
The goal of periodontal treatment is to arrest the progression of periodontal disease and if
possible reverse some of the effects with regenerative therapies. Removal of the harmful
bacterial biofilm is completed through scaling and root planing. Scaling and root planing utilizes
periodontal scalers and curettes to mechanically remove plaque and calculus off tooth and root
surfaces, and then smooth out root surfaces to remove infected dentin and cementum that can be

impregnated with etiological factors that cause inflammation. Scaling and root planing is the
primary and initial modality of treating periodontitis, however, the effectiveness of the nonsurgical treatment can be limited by the severity of periodontal disease and numerous local
factors such as cervical enamel projection (CEP), root grooves, enamel pearls, cemental tears,
furcations, etc. The efficacy of scaling and root planing is dependent on the initial probing
depths. In deep, > 6 mm pockets, only 32% of the surface were calculus free after Scaling and
root planing group. On average, scaling and root planning was shown to reduce probing depths
by 1.56 mm and have an attachment gain of 0.52 mm3. However, even with the reduction in
probing depth and gains in attachment, long term studies have shown that over time non-surgical
therapy is not as effective as surgical therapy especially as the severity of periodontal disease
increases 4,5.
Non-surgical therapy is the initial step for managing periodontal diseases, which usually
results in a repair of the periodontium with the attachment of long junctional epithelium to root
surface. The curetted root surface may be repopulated by 4 different types of cells: epithelial,
gingival connective tissue, bone and PDL cells. Depending on the cells which repopulate the root
surface, different attachments may form. Long junctional epithelium healing has no new CT
attachment and is just epithelial downgrowth (reattachment). However, if new CT attachment is
formed through repopulation by PDL, then new attachment can occur. Similar healing occurs
through surgical therapy however there is increased probing depth reduction at the expense of
attachment levels. In more severe cases of periodontitis intrabony defects, depending on the
morphology of defects it can be treated with regeneration. The term regeneration is defined as
the reconstitution of a lost or injured part, which in periodontics would be the reconstitution of
the periodontal ligament, cementum and bone.
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Guided Tissue Regeneration and Periodontal Regeneration
Guided tissue regeneration attempts to regenerate the lost periodontal structure by
excluding the epithelium from the root surface allowing for bone, cementum, and PDL to
regenerate. The idea that the PDL has the ability to regenerate was originally proposed by
Melcher where he hypothesized that the periodontium has four separate compartments of
connective tissue (CT) in the periodontium: the gingival corium, periodontal ligament (PDL),
cementum, and bone6,7. Therefore, for regeneration to occur, the regeneration of periodontium
must come from the bone and PDL. The PDL tissue contains a population of Mesenchymal Stem
Cells (MSCs) which are multipotent stromal cells that can differentiate into multiple cell
lineages. Mesenchymal stem cells are essential for osteogenesis and cementogenesis in the
development of the periodontium which give rise to cementoblasts, osteoblasts, fibroblasts,
myofibroblasts, endothelial cells nerve cells and epithelial cells. The multipotentiality of MSCs
is believed to be crucial for regeneration8.
The regenerative potential of the periodontal ligament was demonstrated by Nyman in
monkeys with guided tissue regeneration technique, which showed that by excluding the
epithelium in surgically created defects, the preference was given to periodontal cells to
repopulate the area and regenerate the periodontium9. The limitation of the study was that the site
was not previously diseased and that the defects were created surgically. Gottlow, later
demonstrated that with previously diseases root surfaces it was also possible to regenerate the
periodontium10. With epithelial exclusion, coagulum is formed and inflammatory cells infiltrate
the area removing necrotic tissue11. MSCs from nearby bone marrow and periodontal ligament
then migrate into the defects and begin to differentiate into tissue specific cells such as
osteoblasts, PDL cells and cementoblasts. At the same time, tissue specific extracellular matrix is
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produced. With the formation of blood vessels more MSC’s are brought to the defect, with
eventual regeneration of the periodontal complex. The origin of the regenerative cells was
confirmed by Iglhaut through histologic and autoradiographic analysis, indicating that bone and
PDL tissue compartments supply cells to a periodontal wound in surgically created periodontal
spaces 12. The mesenchymal stem cells embedded within the bone and PDL are the at the center
of the regenerative events, and often these cells are considered as a reservoir for healingpromoting factors because of their trophic and immune-modulatory activities13. The need for
MSCs is vital for regeneration otherwise the defect will be dominated by fibrotic cells leading to
non-functional scar tissue, referred to as tissue repair.
Over the years numerous techniques have been developed to regenerate periodontal
tissues, including placing graft substitute material within a periodontal defect in combination
with some type of resorbable or non-resorbable periodontal membrane, membrane alone, bone
substitute in combination with biological material, biological material alone, etc. Although
successful results were observed, they are highly unpredictable and the outcome is still largely
depend on defect morphology(depth, width, number of walls), particulate size, ability of surgeon,
correct material chosen for the defect, stability of graft, ability for angiogenesis, sufficient space
for progenitor cells to populate the area, and stability of the periodontal complex14. In Froum’s
study where osseous coagulum was compared versus open flap debridement it was showed that
bone fill was an average 3.64mm in 3 wall defects, 3.21mm in 2 wall defects, and 2.42mm in 1
wall defects, whereas open flap debridement showed 1.38mm, 1.03mm, and 0.16mm
respectively15. Although the grafted sites were deeper in this study, it does show that the more
bony walls a defect has the better regenerative potential is possible due to greater surface area
and access to MSCs from the bone and periodontal ligament. Similarly, using Gore-tex
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membrane Cortellini showed that 3 wall defects were filled by 95±6.2%, 2 wall defects were
filled by 82%±18.7% and 1 wall defects was only filled by 39 ± 62.4%. These results again show
that the increased number of bony walls the better regenerative outcome is possible16. Lastly, in
furcations, Murphy and Gunsolley demonstrated in their systematic reviews and meta-analysis
that class 2 furcations have the best regenerative outcomes, due to the ability to have sufficient
space to maintain and stabilize graft material within the sites17. It was found that within class 2
furcations both membrane and graft material enhanced vertical probing depth reduction,
horizontal attachment level, and horizontal open attachment level gain17. Often clinicians are
faced with varying morphological defects that are not ideal. Such irregular defects present a
significant challenge for regeneration, partly might due to a decreased access to mesenchymal
cells from the neighboring bone and periodontal ligament.
Bone Substitutes
Bone substitute materials vary from autografts (cortical ⁄ cancellous bone, bone marrow),
allografts (demineralized freeze-dried ⁄ freeze-dried bone), xenograft, and alloplastic materials
(ceramics, hydroxyapatite, polymers and bioglass). New bone formation can occur by three
mechanisms utilizing bone substitute materials can occur by three mechanisms: osteogenesis
osteoinduction, osteoconduction. Osteogenic potential is defined as the ability to have vital
osteoblasts within the grafting material that allow for bone formation. Osteoinduction is defined
as the stimulation of osteoprogenitor cells (mesenchymal cells) to differentiate into osteoblasts
that produce new bone formation. Osteoconduction refers to the grafting material acting as a
scaffold for new bone formation from host bone cells. Autografts have osteogenic,
osteoconductive and osteoinductive potential. Allografts have osteoconductive and
osteoinductive potential depending on the amount of mineralization within the graft, and lastly
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alloplastic materials are limited to a osteoconductive potential. In periodontal regeneration,
autogenous bone and bone marrow is the “gold standard” of grafting because there are MSCs
within the graft which can differentiate into multiple cell types favoring the regeneration process.
However, the limitation to autogenous grafting is that often a second site is needed, increased
patient morbidity, insufficient autogenous bone, and poor quality autogenous bone.
As a substitute to autogenous bone, allografts are a common substitute used to filled
osseous defects and can come in a combination of mineralized freeze-dried bone allograft
(FDBA) and demineralized freeze-dried bone allograft (DFBDA). In early regeneration studies
DFDBA was used for periodontal defects because of its osteoinductive ability. Urist and Strates
first demonstrated that demineralized bone has osteoinductive potential through bone formation
in extraskeletal sites18, which led clinicians to believe that DFDBA is an excellent material bone
substitute. The osteoinductive potential is from remaining bone morphogenic proteins in the
processed graft, where it was shown that BMP-2, BMP-4, and BMP-7 are present19.
Osteoinductive capabilities of DFDBA often vary between tissue banks and same batches of
graft material, which could be due to inactive proteins within the graft, insufficient quantities,
processing methods, age of donor, and medical status 20,2122. Initially it was believed that due to
presence of BMP within DFDBA, the bone graft would be superior in regeneration, which was
shown in early studies23, however based on meta-analysis and various clinical studies there was
no difference in the ability to treat intrabony and furcal defects24–26. The lack in superiority of
DFDBA over FDBA is due to the heterogeneous nature of the studies, processing methods used
by different tissue banks, variance in surgical skill, etc
A substitute to allografts and autografts are alloplasts, which are synthetic inert bone
substitutes. A commonly used alloplast is hydroxyapatite which is a made of calcium phosphate,
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the primary constituent of bone mineral. Alloplasts have been used for regeneration based on
properties of being highly adsorptive and osteoconductive. Although numerous bone substitute
grafts can be used for periodontal regeneration, they are often osteoconductive and not inductive
and do not have the potential to induce neighboring MSCs for regeneration, therefore
supplemental biological materials can be added to the graft to improve the osteoinductivity.
Biologics
Although bone substitute materials are commonly used in periodontal defects, there is
still clinical unpredictability, therefore additional materials such as biologics can be added to
bone substitutes or be used alone for regeneration. The biologics can range from the delivery of
stem cells or different recombinant proteins consisting of Enamel Matrix Derivative (EMD),
platelet rich plasma (PRP), bone morphogenic proteins (BMP), platelet derived growth factor
(PDGF), or synthetic peptides27 One of the most commonly used biologics is EMD, which is a
protein/peptide mix derived from porcine teeth. EMD induces cementogenesis and is a tissue
healing modulator that helps stimulate periodontal regeneration. EMD has been shown to be
effective in periodontal regeneration alone or in combination with bone graft substitutes. Platelet
derived growth factor (PDGF) is derived from platelets, macrophages, and osteoblasts. PDGF
stimulates intracellular pathways for DNA and protein synthesis and stimulate cell proliferation.
It has been used in both periodontal and periimplant defects. Although both EMD and PDGF
have been shown to be effective in periodontal regeneration and healing, limitations remain
regarding the application of growth factors. EMD has a gel like consistency and if primary
closure of the defects is not obtained the displacement of the growth factors takes place and often
the gel like consistency is not sufficient in maintaining space within the defect leading to soft
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tissue collapse. Additionally, the varied results in literature may be due to a low efficiency in
targeting MSCs to allow further expansion and functioning during the healing process.
Even with modern biologics, the degree of tooth-supporting tissue regeneration is still
suboptimal and usually results in less than 50% bone regeneration and 20% horizontal defect
fill28. One of the factors that makes regeneration unpredictable is the varying morphology that is
encountered with each periodontal defect, inefficiency of directing MSCs into periodontal wound
healing sites, and engraftment of MSCs which have made regeneration difficult29. Periodontal
regeneration is not a passive process, but rather a dynamic process that includes processes such
as early protein expression, cell apposition, remodeling and maturation of the healing site8. Cell
based therapies and homing of mesenchymal cells to accelerate and capitalize on the dynamic
process of regeneration have drawn increasing attentions in the field.
Emerging Concepts
Cell therapy is being intensively investigated for accelerating periodontal regeneration
through direct delivery of stem cells, mainly MSCs, to the periodontal defects. MSCs from bone
marrow (BMSCs) are the most widely studied partly because they are easily accessible.
Transplantation of BMSCs induced periodontal regeneration that was characterized by new
cementum, bone and PDL ligament formation in experimental periodontal defects in rats, rabbits,
mini pigs, and dogs30. By cell-labeling techniques, the differentiation of exogenous BMSCs to
cementoblasts, PDL fibroblasts, and alveolar bone osteoblasts was confirmed31,32. Although a
few preclinical and clinical studies have suggested the potential of MSC cell therapy in
periodontal regeneration, many challenges remain in current treatment strategies based on
exogenous stem cells. For example, a sophisticated cell culture facility is commonly needed for
cell expansion before clinical use. There will be difficulties in the transportation of cells if a
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central culture facility is used. Other issues include the lack of cell sources, safety concerns
regarding the use of animal serum and potential tumorigenic effects. Furthermore, only a small
percentage of stem cells remain after weeks of engraftment29,33. Therefore, approaches to target
endogenous MSCs in patients are highly desirable both from a clinical and financial standpoint.
Recently a MSC affinity peptide (E7, EPLQLKM) was discovered through phage display
technology34. The peptide showed a high affinity to BMSCs across rat and human species. E7
peptide has the ability to increase the homing and proliferation of MSCs36,37, enhance the
infiltration rate of stem cells34, reduce inflammatory response35, and promote ligament-bone
healing and cartilage regeneration35 . Covalent conjugation of E7 to polycaprolactone (PCL) and
poly-L-lactide (PLLA) bio-polymers significantly enhanced the attachment of BMSCs to the
material surface and increased cell spreading. The E7 functionalized biomaterial was also able to
stimulate MSCs proliferation during in vitro culture.35 When bone marrow was cultured in the
E7-conjugated cell culture devices, enrichment of MSCs was observed compared with those
grown with E7, suggesting a use for MSC enrichment bio-incubators36.
Recently, Lin group tested E7 peptide on human PDL cells against a scramble control
(scramble sequence of E7) and DMSO to determine its affinity of PDL and BMSC cells. E7 was
shown to have highest affinity for PDL progenitor cells and BMSC, and in addition E7 had a
stronger affinity than RGD, a well investigated peptide of type 1 collagen. The affinity to PDL
and BMSC was strong regardless of the modification of the terminal amino acid, suggesting a
future protein engineering to modify the function of this peptide. Even though preliminary data
shows strong affinity for PDL and BMSCs, from a clinical standpoint the addition of bone
substitute material within periodontal defects allows space maintenance and tissue support for
mesenchymal stem cells to migrate into the defect. Although it may seem logical to combine
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peptides with bone grafts to induce greater bone growth, common issues with peptide therapy
combined bone graft substitutes is the inability to have a controlled release of peptide. Often
combination of growth factors with bone grafts results in a bolus release which can leading to
immediate degradation and consumption of the peptide within a 24-hour period. In addition to
the fact that growth factors have a very short half-life in vivo, superphysiological doses are
commonly used in clinics. rhBMP-2 loading dose is usually a million times higher than
physiological levels and many times higher than needed in non-human primates and mice.37 Such
high dosages of growth factors are often related to various systemic side effects as well as high
treatment cost. Therefore, a peptide that has the ability to have a controlled release and strong
bone conjugation would be able to promote a sustained regeneration.
As mentioned, hydroxyapatite is a widely used osteoconductive bone grafting material
based on its similar structure to bone, and has been compatible with linking different peptides
and proteins for bone regeneration38,39,40. Numerous linking mechanisms to bone matrix have
been identified from endogenous bone matrix proteins. For example, Osteocalcin41, Bone
sialoprotein BSP42 and Osteonectin43 bind to bone through γ-carboxyglutamic acid41. Such
mechanisms inspired researchers to develop bone binding peptides/proteins. Phosphorylated
amino acids or negatively charged amino acid sequences such a poly-Asp chain44 have been
utilized to modulate bioactive peptides for stronger retention to hydroxyapatite. One binding
mechanism utilizing polyglutamic acid allows different peptides to conjugate to bone/bone graft
materials and increase the binding strength by nearly ten times45, and allows for the retention of
amino acids for up to 3 months in different allograft materials36. Studies have not only shown
that by increasing the number of glutamate residues36 there is an increased binding strength to
bone domains but by adjusting the number of glutamate residues, one can tune the release rate of
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the amino acid. Utilizing the bone binding capabilities of polyglutamic acid and MSC homing
ability of E7 peptide, we designed a novel peptide E7HA7 to improve the bioactivity of bone
graft material by attracting and maintaining MSCs at the healing site. In this study, we
investigated the in vivo bioactivity of this peptide.
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Specific Aims
In this two-part study, we first tuned E7-HA with two glutamate residues (E7HA2) and
seven glutamate(E7HA7) residues to determine which peptide modification has the greatest
retention with hydroxyapatite in vivo. In part 2, we tested whether E7HA7 enhances the
osteoinductive potential Demineralized Bone Matrix (DBM) in a murine ectopic bone formation
model. Our hypothesis is that a greater retention of peptide E7 will occur with the
heptaglutamate residue based on the greater number of anionic sites from glutamate. In aim 2 our
hypothesis is that the conjugation of E7HA7 with DBM will enhance the osteoinductivity of the
bone substitute material.
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Methods and Materials

Aim 1: E7- Peptide In-vivo Release Kinetics
Experimental Design
All procedures performed on animals followed protocols approved by the institutional Animal
Care and Use Committee (IACUC) at Virginia Commonwealth University. Synthetic
hydroxyapatite (HA) discs were used as a model to mimic mineralized bone grafts. One E7
peptide without any glutamate modifications was attached to the E7 directly and two HA binding
domains, one with seven glutamates (E7HA7) and the other with two glutamates (E7HA2), were
linked to the bone grafts. All peptides were labeled with Fluorescein isothiocyanate (FITC)
fluorescent marker at the N terminus for in-vivo fluorescence detection.
Peptide Synthesis
Peptide synthesis: The following custom peptides were synthesized from Genscript Co.
(Piscataway, NJ):
Name
HA Disc
E7
E7HA-2
E7HA-7

Sequence
None (control)
EPLQLKMCK-(FITC)
EEEPLQLKMCK-(FITC)
EEEEEEEEPLQLKMCK-(FITC)

In order to facilitate the conjugation of FITC to the peptides, a cysteine is added to N terminus.
All peptides were reconstituted in DMSO to achieve a concentration of 2 mg/mL, aliquoted and
stored at −20°C. HA disks (5mm in diameter, 1.6mm in thickness) that designed for 96-well
plate were obtained from 3D-Biotek (Hillsborough, NJ, USA). To track binding and release
kinetics, variations of these peptides were synthesized to contain Fluorescein (FITC) tags.
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Peptide coating
The peptide solutions were added to HA scaffold in sterile 96 well plate (100 ul/well) with
concentrations of 0.2 mM with continuous agitation at room temperature. After 24 hours,
supernatants were aspirated completely and surfaces were briefly washed three times with
phosphate buffered saline (PBS) for 5 min with agitation. The HA discs were dried and stored
under sterile conditions at room temperature in a dark environment until needed.
Surgery
All procedures performed on animals followed protocols approved by the Institutional Animal
Care and Use Committee (IACUC approved protocol number: AD10001162) at Virginia
Commonwealth University. Animals were ordered two weeks ahead of time to allow rats to
acclimate to the environment and were fed ad libitum. Rats were randomized by independent
examiner and were weighed prior to anesthesia, at week 2,4 and 8. Weights were stabilized and
did not fluctuate significantly during examination, no signs of stress were present to the animals.
General anesthesia was administered to Sprague–Dawley rats, using methoxyfluorane for all
surgical procedures. All the animals were administered with Buprenophine SR LAB to release
the pain stress caused by the surgery. Two one cm midsagittal incisions were made on the dorsa,
and two subcutaneous pockets were created with hemostats via blunt dissection on each side of
the incision (Figure 1). Discs with different coatings were randomized per animal by a separate
examiner and surgeon was blinded to the identity of the discs. Four discs were implanted into
each rat, each disc from a separate group. Once discs were inserted, sites were closed with
staples and swabbed with iodine at incisions lines. A total of 13 rats had four discs implanted
subcutaneously.
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In-vitro Fluorescence Imaging
In vitro Fluorescent images were taken at 0,2,4,8 weeks. All fluorescent images were captured
with CRi Maestro In-vivo spectral imaging system (Cambridge Research & Instrumentation, US)
(Woburn, MA) (Figure 1). At each time point except week 0, four animals were euthanized using
CO2, once animal was euthanized two midsagittal incisions were made in similar area as
previous surgery. Scaffolds were retrieved with the surrounding tissue (about 4 mm thick tissue
around the scaffold was retrieved with the scaffold) and immediately soaked into 10 % neutralbuffered formalin. Discs were immediately placed in dark container so that fluorescence marker
would not be altered by ambient light. At 2w, 4w and 8w, residual peptides within the HA
scaffolds were measured with Maestro imaging system (Figure 1). There were 4 scaffolds for
each treatment group at 2-week and 4-week time points, and 5 scaffolds/treatment group for 8week time point. In total, there were 52 scaffolds and 13 rats.
Aim 2: Osteoinductive potential of DBM in Combination with E7
Sample preparation
In this study, Demineralized Bone Matrix Allograft (DBM) was procured from the
Musculoskeletal Transplant Foundation (Edison, NJ). All samples provided to the surgical and
evaluation team were coded to blind the reviewers to the tissue bank source as well as donor age
and sex. Four different groups of DBM were tested; Active DBM (positive control) where active
protein factors were present on the bone matrix from the normal tissue processing from the tissue
bank. All tissue banks follow a general system that involves cleaning, defatting, and disinfecting
cortical bone; grinding the defatted bone to particle sizes between 400 and 1000 mm;
demineralizing the bone particles in dilute hydrochloric acid solutions, resulting in a residual
calcium content of <8% per the American Association of Tissue Banks standards; and freeze-
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drying the final product46. Active DBM from the same lot was heated for twenty-four hours at
105˚C to inactivate any biologically active protein factors present and served as Inactive DBM
(negative control). E7HA7 was conjugated to both and Inactive and active DBM matrix. Particle
size was kept between 400-1000 microns, which is the typical size bone graft used for
periodontal grafting. Capsules were filled with 20mg of active or inactive DBM with/without E7
peptides. Capsules were used to facilitate implantation and help localized the bone graft and
prevent displacement in-situ. All samples were prepared under aseptic conditions and were
stored at room temperature until samples were ready for implantation.
Experimental Design
The second part of the study was conducted under a protocol approved by the Institutional
Animal Care and Use Committee at Virginia Commonwealth University. Sixteen 8-week-old
nude athymic mice were divided into four groups: Active DBM (aDBM), Active DBM-E7
(aDBM-E7), Inactive DBM (iDBM), and Active DBM-E7 (iDBM-E7).
Implantation Protocol
An ectopic bone formation model was used to test the bioactivity of E7HA7 and the
enhancement of osteoinductivity when combined with demineralized bone matrix. Athymic nude
mice were anesthetized by inhalation of 5% isoflurane gas. A 1cm incision along gastrocnemius
muscle was made and a longitudinal split with blunt dissection was created per leg. One gelatin
20mg capsule containing a variation of DBM was inserted into the muscle pouch and was closed
with a wound clip (N=2/animal) (Figure 3). 8 implants were placed in each group with a total of
16 animals.
The mice were housed in appropriate conditions based on their immunocompromised
status and were given food and water ad libitum for 35 days. This time period was chosen based
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on previous experiments demonstrating that 35 days was sufficient time for osteoinductive
activity to take place in this animal model. Animals were sacrificed at 35 days using carbon
dioxide asphyxiation. The hind limbs were disarticulated and immediately placed into 10%
formalin solution for future histological and morphometric assessment.
Morphometric Analysis
The ability of the samples to induce new bone were quantitatively analyzed by two separate
blinded examiners using Bruker Skyscan 1173 MicroCT (Billerica, MA) (Figure 3). Each
disarticulated hind leg was placed inside a plastic test tube fitted with cotton gauze to stabilize
the leg from moving during imaging. The plastic test tube was placed on the platform in the
machine and imaged. Once raw images were created, a superior and inferior threshold was made
for each image to exclude any areas that could have bone fragments or noise from disarticulation.
The examiner went through each cross section of each microCT slice, a region of interest was
made around the long bones of the leg to eliminate to subtract the region of interest to determine
the amount of new bone formation in each sample (Figure 4, Figure 5, Figure 6, Figure 7).
Similar imaging parameters were selected for each sample and new bone formation was
determined by new bone volume formation in mm3.
Histomorphometric analysis
Samples were commercially processed (Histion, Everett, WA, USA). Femurs were embedded in
methyl methacrylate, and one ground section from each specimen was stained with Hematoxylin
and Eosin staining. Sections were imaged with an AxioCam MRc5 camera and Axio Observer
Z.1 and analyzed using ZEN 2012 Blue Edition software (Carl Zeiss Microscopy, Oberkochen,
Germany).
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Statistical analyses
Part 1
The study is a two-way design (four treatments and 4 time periods), with animals observed
across time. This within-animal dependence is taken into account in the analysis. The
interventions are compared using a repeated-measures mixed-model two-way ANOVA.
Fluorescence is severely skewed and so the log-transformed values are used for analyses. The
least-squared mean estimated values for each group are back-transformed to the original scale,
yielding geometric mean values. Differences between treatments are identified at each week
using pre-specified contrasts. All analyses were performed using SAS software (JMP pro version
13.2, SAS version 9.4, SAS Institute Inc., Cary NC).
Part 2
The study is a two-way design (Active vs Inactive and E7HA7 yes vs no), with the interventions
assigned to either the left or right leg of the animal. This within-animal dependence is taken into
account in the analysis. The interventions are compared using a repeated-measures mixed-model
two-way ANOVA. The bone volume (in mm3) is severely skewed and so the log-transformed
values are used for analyses. The least-squared mean estimated values for each group are backtransformed to the original scale, yielding geometric mean values. Differences between the four
groups are identified by Tukey’s honestly significantly different multiple comparison procedure
(at alpha = 0.05).
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Results

Weights among the animals remained stable throughout the experiment. No animal deaths were
observed throughout the experiment, and all animals tolerated the procedures well.
Aim 1: Retention of E-7 Peptide on HA discs
Qualitatively, at week 0 discs coated with E7-HA2-FITC had the strongest fluorescence signal,
especially on the perimeter of the discs. Qualitatively, E7-HA7-FITC groups had the highest
fluorescence intensity at 2,4, and 8 weeks. Interestingly, fluorescence was mainly noted on
perimeter of discs. The fluorescence intensity of each group at the four time periods is shown in
(Figure 8). Fluorescence values are strongly skewed with higher variability occurring at brighter
intensity. Based on the skewed intensity a two-way ANOVA analysis analyzed the logtransformed values to equalize the variability within groups. The back-transformed values for
each group are summarized in (Table 1). In the peptide releasing study, all three peptide groups
had statistically stronger fluorescence signals at all the time points compared to control discs.
E7HA7 coated scaffolds had stronger fluorescent signals at all three time points compared to
other groups, indicating a longer retention and stronger affinity for HA scaffolds. E7HA7
showed slower peptide release from scaffolds in comparison to other groups, being statistically
significant at week 2 compared to E7, and to E7HA2 at week 4 and week 8(Figure 8,Figure 9).
Aim 2: The osteogenic potential of bone graft material combined with E7HA peptide
New Bone Volume Formation
The median values for new bone formation are: iDBM=0.041mm3, iDBM-E7=0.071mm3,
aDBM=0.138mm3, and aDBM-E7=0.192mm3 (Figure 10). As is typical with volume
measurements, the values were skewed. The two-way repeated-measures ANOVA was
performed on the log-transformed bone levels. There was a significant difference between the
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active and inactive groups (P=0.008), but no significant difference between the E7 vs E7HA7
groups (P=0.187). Although new bone formation was greater in aDBM-E7, significant difference
was only found when compared to the iDBM group (Table 2) .When comparing controls, aDBM
vs iDBM, aDBM had a greater bone formation than iDBM, however the difference was not
statistically significant. The addition of E7HA7 increased the bone volume 1.48 times (P=0.48)
in the inactive DBM group and 1.98 times (P=0.23) in the active DBM group, but the additive
benefit did not reach statistical significance.
The results of the multiple comparison procedure are shown in Table 3. As mentioned
earlier, the only statistically significant difference of new bone formation was between aDBME7 vs. iDBM, where aDBM had 5.6 times more new bone formation present (p =0.03). It is
interesting to point out that, if we only compare the active DBM to inactive DBM (without
E7HA7 coating), although more bone formation (2.82 times as high) was seen in the active DBM
group, the difference was not statistically significant (P=0.27).
Histological Observations
All photomicrographs were screened, and one representative sample was chosen from
each group to be included for qualitative assessment. Photomicrographs of Inactive samples
showed DBM particles, surrounded by a combination of connective tissue, adipose tissue, and
muscles tissues. The inactive samples did not show any new bone formation within the samples.
No new bone formation was demonstrated by a homogeneous color of bone particle with the
absence of osteoclasts, osteoblasts, and hematopoietic cells surrounding the periphery of the graft
or within lacunae. No inflammatory cells were noted in the inactive samples surrounding bone
particles (Figure 11). A general trend noticed in active samples was fewer DBM particles
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present, possibly indicating that heat treatment of the bone graft could have led to increased
resorption of the DBM particles
Active groups demonstrated DBM particles, surrounded by a combination of connective
tissue, adipose tissue, and muscles tissues. When comparing both active and inactive samples
there was more presence of bone graft in the active samples, indicating less resorption of the
bone graft. Although a larger quantity of bone graft was present in active samples, there was
minimal to no new bone formation present seen by uniform color of the residual graft material
and lack of bone marrow, immature bone, and hematopoietic cells (Figure 12).
The addition of E7 to inactive groups showed similar morphology to inactive groups,
however the addition of E7 showed less resorption of graft materials and the presence of a
greater number of particles in comparison to iDBM samples by themselves (Figure 13). More
robust osteoinduction was present in active samples in combination with E7 peptide. Presence of
Ossicles (bone-like tissue surrounding an area of bone marrow-like tissue) was present in
aDBM-E7 samples (Figure 14,
Figure 15). Ossicles are indicative of mature bone formation. In addition, presence of
osteocytes and hematopoietic cells was present in aDBM-E7 samples. Since limited new bone
formation was present in the aDBM alone, and more mature bone formation was present with the
addition of E7 peptide in several samples is a possible indication of osteoinductive enhancement
of the DBM.
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Discussion

Numerous bone substitute materials are used for periodontal regeneration, each one with their
positive and negative attributes. Limitations of synthetic HA are that the alloplastic material has
good osteoconductive properties but lacks the osteoinductive properties. However, surface
functionalization of HA through the addition of osteoinductive molecules can enhance the
regenerative outcomes.
The success in periodontal and bone regenerative procedures is still highly dependent on
the defect morphology and regenerative potential of the patient. Previous studies have shown that
there are numerous modalities for enhancing osteoinductivity of bone material, such as the
delivery of stem cells, platelet rich plasma, and recombinant proteins (Platelet Derived Growth
Factor BB and bone morphogenic proteins). Although there are benefits to adding various
enhancing products, the molecules are passively adsorbed to the surface and have low binding
capacity to the grafting material, limiting effective release control kinetics. To enhance bone
binding and release kinetics various mechanisms mimicking the endogenous bone matrix
proteins, such as GLA protein, osteonectin and bone sialoprotein, have been identified. A bone
binding motif consisting of negatively charged amino acids such a glutamic acid is one of them.
One of the first groups to identify the affinity of glutamic acid to HA crystals was Fujisawa, who
showed that through degradation of osteonectin, the residual binding residues were rich in
glutamic acid45. In later studies, Fujisawa compared the binding of osteoblastic cells to HA
coated BSP, osteonectin, bovine serum albumin and Glu7-Pro-Arg-Gly-Asp- Thr (E7TPRGDT).
E7TPRGDT was used because it contained both a putative hydroxyapatite- binding sequence and
the RGD sequence, a cell binding motif. E7TPRGDT being 1/50 the size of BSP had similar
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ability to recruit osteoblastic cells as BSP, and the dissociation constant was 500x times greater
than that of BSP.
The Culpepper group has also demonstrated the enhanced coupling of polyglutamic acids
to bioactive peptides for enhanced retention and controlled release in vitro and in vivo models.
DGEA (Asp-Gly-Glu-Ala), a collagen derived peptide were synthesized with variable length
polyglutamate chains (diglutamate (E2), tetraglutamate (E4), and heptaglutamate (E7) and
adsorbed on to HA discs and allograft particles and retention was determined36. In all mediums
and assays E7>E4>E2 had increased peptide loading and retention after 5 days36. The bound
peptide released ranged from in E7-DGEA was <10% after 5 days in Saline agitation and ~35%
in serum containing media, while DGEA alone was nearly 90-100% released in both medias
after a 5 day period36. In similar medias, improved retention was noted on HA discs vs Allograft,
however different binding substrates (HA discs vs allograft particle) was used.
In Polini’s study comparing release kinetics of E7 (polyglutamate), Osteocalcin (OCN),
and salivary statherin (N7) adsorbed to similar HA discs used in our study, the results were
comparable to release kinetics present in our study. Overall E7 had the greatest retention
compared to OCN and N7. When these retentive molecules were tested on their own at a 1month time period, 75% of E7, 30% of OCN, and 25% of N7 was still retentive on the HA
scaffolds47. When E7 was combined with osteogenic molecules such as Osteogenic Growth
peptide (OGN) and Bone morphogenic Protein -7 (BMP-7) the addition of osteogenic molecules
did not affect peptide retention and at a 1-month time point nearly 60% of the peptide was
retained. The combination of an osteogenic molecules with E7 did not affect the binding and
releasing properties of E7.

23

Similarly, in our study when comparing varying polyglutamate chains, the E7HA7 had
the greatest retention on discs over an 8-week period. E7HA7 showed slower peptide release
from being statistically significant at week 2 compared to E7, and to E7HA2 at week 4 and week
8. Culpepper showed that DGEA alone had quickest release, nearly 100% released by 5 days and
E2 had quicker releasing at all time points in comparison to E7. In our current experiment over
an 8-week period although E7HA7 had greatest retention, interestingly E7 alone vs E7HA2 had
greater retention at 4 and 8-week time points. However, this was not statistically significant. In
addition, when examining the release curves of the various groups it is evident that at the 1-week
time point E7 and E7HA2 were nearly one hundred percent released, where E7HA7 still has
approximately 50% of peptide bound to the HA discs. Reasons for greater retention could be due
to uneven distribution of peptide along the HA surfaces, where more would accumulate on the
edge of the discs as opposed to the center of the discs. Greater accumulation along the edge of
the discs could be speculated to having a greater surface roughness and increased surface area for
binding for the bioactive peptides within the study. In addition to greater accumulation on the
edges, the stronger fluorescence intensity seen from the edge of the discs could also wash out the
fluorescent intensity that may be present on the middle of the discs. Quantification of peptide
release in our study was difficult due determine to a different model used in comparison to the
Culpepper studies, where they used serum containing media or saline media, our studies used a
subcutaneous environment of rats making it difficult to have a standard to compare direct
release.
In another study by the Culpepper group they examined the effects of Heptaglutamate
domain coupled with DGEA peptide on HA discs and HA discs coupled with electrospun
scaffolds48. Similarly, in their studies, in a subcutaneous model DGEA coupled with
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Heptaglutamate had the greatest retention on HA discs coupled with and without electrospun
scaffolds, in comparison to DGEA alone. The results indicate that surface modification of bony
substrates with bioactive peptides can serve as a vehicle for long term release of regenerative
molecules. Modulating the release of the bioactive peptides, E7 has the potential to recruit
autologous bone marrow derived, periodontal, and pulpal stem cells to the periodontal defect for
regeneration.
Numerous experiments including ours have shown increased retention of peptides to both
hydroxyapatite and allograft materials through ionic coupling of polyglutamate domains to
endogenous bone matrix proteins. Demineralized allograft materials, another popular graft for
regeneration due to its exposed osteoinductive proteins on the surface have been shown to be
successful in periodontal regeneration. However, the osteoinduction potential often varies among
various demineralized allografts due to inactive proteins within the graft, insufficient quantities,
processing methods, residual calcium levels, age of donor, and medical status. To our
knowledge, the addition of modified E7 (EPLQLKM) peptide to DBM, is one of the first in-vivo
experiments to test the additive effects to osteoinductivity of E7 to DBM.
The additive effect of the E7HA7 to DBM increased bone volume about 1.5 times in the
inactive DBM and about two times in the active DBM. Although the osteoinductive
enhancement of E7 is not statistically significant, it is suggestive of an enhancement of the
osteoinductive potential. The lack of statistical significance for new bone formation could be due
to several reasons. As shown initially by Fujisawa, when heptaglutamate was coupled with
PRGDT, there was a positive correlation with peptide binding with calcium ions, and negative
correlation with phosphate ions, measured through fluorometry45. Based on the AATB, the DBM
used in this experiment has less than 8% residual calcium present according to the manufacturer
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website which suggests that only a small percentage of E7 heptaglutamate would have been
bound to the graft. Additionally Culpepper, demonstrated that, with electrospun
polycaprolactone (PCL) scaffolds compared to HA discs under constant wash for 7 days, PCL
alone was insufficient for retaining E7-DGEA, and that HA is needed to facilitate binding48.
The intent of demineralization of allograft is to expose the proteoglycan/collagen matrix
and protein factors such as bone morphogenic proteins. Zhang, showed that FDBA
demineralized with hydrochloric acid, depending on the demineralization time the residual
calcium by weight can drop from ~32% to ~1% if demineralized up to 300 minutes22. In
addition, Zhang demonstrated that osteoinductivity of DBM can also vary based on particle size.
The particle size with most osteoinductive potential ranged from 500-710 microns, whereas
particles less than 250 microns had significantly reduced osteoinductive potential compared to
other particle sizes22. Demineralized bone was used in this intramuscular model so that new
calcification/osteogenesis could be quantified through micro-CT imaging.
The weak enhancement of E7 to the osteoinductive potential of DBM and range of bone
volume formations can be explained due to several reasons. Based on histology from our study it
was evident that very weak new bone formation and osteoinduction was present in the active
DBM group. According to Schwartz et al, the variability and lack of osteoinductivity could be
due to processing methods of the tissue bank, insufficient time for the new bone formation to
occur, batch used in the experiment is not osteoinductive21. The particular batch from our study
could not have been as inductive as other batches, Schwartz found that 18% of the batches had
no osteoinductivity, and 40% had only moderate inductivity20. Lastly, insufficient time could
have resulted in less bone formation. In Schwartz 1996 study bone formation was assessed at day
28 and day 56, where a larger amount of new bone formation was evident at day 56 in
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comparison to day 28. Increased bone volume formation at a later time point was due to a less
robust osteoinductive effect at an earlier time point21. There is a possibility that a longer time
could have resulted in more new and mature bone formation for the active group with and
without E7 with a longer incubation time. Although hardly any new and mature bone formation
was seen in aDBM group, the combination of E7 peptide, did enhance formation of new and
mature bone. The presence of new and mature bone formation presents in several samples only
in the aDBM-E7 group, indicate that there is an enhancement of osteoinductivity with E7
peptide.
The variability in particle size could account for the broad range of volumetric
measurements among groups. Although uniform amount of bone was used among each group,
the small variance in particle size could affect osteogenesis and osteoinduction. The weak
osteoinductive enhancement of E7 could also be due to the residual calcium particles left over
within the graft. Since demineralized bone was used, the low concentration of calcium within the
graft could account for a weak binding affinity of E7 peptide to the demineralized bone, which
would affect osteoinductive enhancement. Although a high binding affinity was shown for HA
discs and E7HA7, no attempts at this time have been made to quantify affinity or retention of
E7HA7 on demineralized bone. Additionally one of the difficulties in mesenchymal stem cell
homing is the low efficiency and engraftment of endogenous mesenchymal cells29. As previously
shown, Bone Marrow Derived Mesenchymal Cells have the ability to differentiate into dental
progenitor cells, the highest engraftment of mesenchymal cells was seen in pulpal and
periodontal tissues as opposed to lung, liver, and adipose tissue32. The reason for higher
engraftment was due to continuous remodeling of periodontal tissue, a connective pathway
between the bone marrow cavity and periodontium of the mandible, and higher expression of
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SDF-1 protein in dental mesenchymal tissues32. Therefore, based on location of particulate
placement as shown in other studies, it may be difficult to home the necessary osteoblasts needed
for osteogenesis.
There are several limitations that apply to this study. In both portions of the experiment a
larger number of samples within each group could have been used yielding a stronger result. In
the second portion of the study, affinity and retention of DBM particulate in combination with
E7 BMSC affinity peptide could have been examined in-vitro to determine binding capabilities
and affinities. Additionally, a mineralized bone graft could have been compared to a
demineralized bone graft to see if there was an additive benefit of E7 to the bone graft. Although
there are limitations to the current model used to determine the benefit of E7 for osteogenesis,
future studies will use periodontal defects to determine the ability of E7 to home in mesenchymal
stem cells.
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Conclusion

Conjugation of E7 to polyglutamate bone binding domain showed long –lasting releasing
kinetics from hydroxyapatite scaffolds. Based on the results, we can conclude that E7HA7
promotes a stronger affinity to the Hydroxyapatite scaffold, with improved retention and
controlled release. The conjugation of E7HA7 peptide to inactive and active DBM slightly
enhanced the osteoinductivity potential of both allografts. Thus, E7HA7 may be used to enhance
bone regeneration for guided tissue regeneration procedures in the future, however further
studies need to be conducted.
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Tables
Table 1. Fluorescence Intensity by Peptide coating group at each Week
Peptide
Fluorescence intensity (au)
Coating
Geo. Mean
95% CI
Week 0 (n=4)
Control
9.1
2.3
35.8
E7-FITC
12,339.6a 3,127.5
48,685.5
E7HA2-FITC 29,518.9a 7,481.7 116,466.2
E7HA7-FITC 15,689.2a 3,976.5
61,901.3
Week 2 (n=4)
Control
2.3
0.6
9.0
E7-FITC
145.2a
36.8
573.1
E7HA2-FITC
925.8a
234.6
3,653.4
E7HA7-FITC
4,224.7a,b 1,070.8
16,668.6
Week 4 (n=4)
Control
0.7
0.2
2.9
a
E7-FITC
132.9
33.5
526.7
E7HA2-FITC
46.7a
11.8
184.1
a,c
E7HA7-FITC
613.1
155.4
2,418.8
Week 8 (n=5)
Control
1.8
0.5
6.0
a
E7-FITC
152.4
44.7
520.4
E7HA2-FITC
77.4a
22.7
264.1
a,c
E7HA7-FITC
540.5
158.3
1,844.6
Notes: Least-squares mean estimated values from a repeated-measures mixed-model ANOVA
were back-transformed to the original units to yield geometric means. Differences were
identified by specific contrasts.

Table 2. New bone volume, by groups
New bone volume (mm3)
ActivityE7HA7 Estimate * 95% CI p-value
Inactive no
0.034a 0.015 0.077
yes
0.050a,b 0.022 0.114
ratio
1.482 0.460 4.773 0.4846
Active
no
0.095a,b 0.042 0.217
yes
0.188b 0.082 0.429
ratio
1.976 0.614 6.364 0.2336
* The superscript values after the geometric mean estimate indicate group differences. Groups
sharing the same superscript are not significantly different, by Tukey’s HSD (P<0.05).
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Table 3. Paired comparisons between groups
Comparison
Ratio
95% CI
Adjusted p-value
Active no vs. Active yes
0.51
0.10
2.46
0.6117
Active no vs. Inactive no
2.82
0.58
13.71
0.2736
Active no vs. Inactive yes
1.90
0.39
9.25
0.6525
Active yes vs. Inactive no
5.57
1.15
27.09
0.0312
Active yes vs. Inactive yes
3.76
0.77
18.28
0.1170
Inactive no vs. Inactive yes
0.67
0.14
3.28
0.8889
Note: Differences on the log-scale, when back-transformed to the original scale are interpreted as
the ratio of the groups compared. Active=active DBM; inactive=inactive DBM; yes=with
E7HA7 peptide; no=no E7HA7 peptide.
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Figures
Figure 1: Disc Implantation in Animals and Fluorescent Imaging for Aim 1

Schematic representation of subcutaneous implantation of hydroxyapatite discs and fluorescent
imaging
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Figure 2: In-vivo Fluorescence Readings a t 0,2,4, and 8 Weeks

0 weeks

2 weeks

4 weeks

8 weeks

E7HA7 peptide coated scaffolds qualitatively have stronger fluorescent signals at 2,4,8 weeks indicating
longer retention and stronger affinity for HA discs. Strongest fluorescence can be noted on peripheries of
disks. (n=4 or 5)

Figure 3: Sky Scan 1173 Micro-CT and Gastrocnemius Implantation Protocol

Surgical Implantation of gelatin capsules containing Demineralized Bone Matrix into
gastrocnemius muscle of athymic nude mice
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Figure 4: Active DBM MicroCT Ectopic Bone Formation

MicroCT rendering of ectopic bone formation. New bone formation can be denoted inside red
circle.
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Figure 5: Inactive DBM MicroCT Ectopic Bone Formation

MicroCT rendering of ectopic bone formation. New bone formation can be denoted inside red
circle.
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Figure 6: Active DBM E7-Heptaglutamate MicroCT Ectopic Bone Formation

MicroCT rendering of ectopic bone formation. New bone formation can be denoted inside red
circle.

43

Figure 7: Inactive DBM E7-Heptaglutamate MicroCT Ectopic Bone Formation

MicroCT rendering of ectopic bone formation. New bone formation can be denoted inside red
circle.
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Figure 8: Fluorescent Intensity by Peptide Coating Group at Each Week

The raw fluorescent intensity of each of the groups at the four-time periods is shown in Figure 8:
Fluorescent Intensity by Peptide Coating Group at Each Week.
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Figure 9: Fluorescence Intensity by Peptide Coating Group at Each Week

Within each week, differences between the four treatments are identified as follows: The “a” superscript
identifies treatments with values significantly different than the control. The “b” superscript identifies
differences as compared to E7-FITC. The “c” superscript identifies differences as compared to E7HA2FITC.
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Figure 10: New Bone Volume (mm3) in Ectopic Model

The new bone volume levels in the 16 animals is shown in the boxplots of Figure 10. The median values for
the four groups were as follows: Inactive=0.041025 mm3, Inactive E7=0.07135 mm3, Active=0.137985
mm3, and Active E7=0.191515 mm3
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Figure 11: Representative Inactive DBM Histology Sample

Photomicrographs of iDBM, sample showing DBM particles, surrounded by a combination of
connective tissue, adipose tissue, and muscles tissues with lack of new bone formation. (stained
with hematoxylin and eosin)
Figure 12: Representative Active DBM Histology Sample

Photomicrographs of aDBM sample showing DBM particles, surrounded by a combination of
connective tissue, adipose tissue, and muscles tissues with lack of new bone formation. (stained
with hematoxylin and eosin)
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Figure 13: Representative Inactive DBM-E7 Histology Sample

Photomicrographs of iDBM-E7 samples showed DBM particles, surrounded by a combination of
connective tissue, adipose tissue, and muscles tissues with lack of new bone formation.

49

Figure 14: Representative Active DBM-E7 Histology Sample

Photomicrographs of aDBM-E7 showing DBM particles, surrounded by a combination of
connective tissue, adipose tissue, and muscles tissues. aDBM-E7 samples showing the
presence of ossicles (bone-like tissue surrounding an area of bone marrow-like tissue) in
the red and black boxes.
Figure 15: Active DBM-E7 Histology New Bone Formation

Photomicrograph of ossicle formed after intramuscular implantation of DBM 5weeks. Note the
Ossicle formed (arrow), New Bone (N), bone marrow (M), Graft (G), Connective Tissue (C).
(stained with hematoxylin and eosin)
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